Abstract
The WNT/β-catenin signaling pathway plays a major role in the development of various tissues, including the adrenal cortex. β-Catenin fulfills a dual role as a structural component in cell–cell adhesion and as the key transcription cofactor of T-cell factor/lymphoid enhancer factor (TCF/LEF).
Keywords
- Familial Adenomatous Polyposis
- Adenomatous Polyposis Coli
- Familial Adenomatous Polyposis Patient
- Adrenocortical Tumor
- Carney Complex
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bienz M (2005) Beta-catenin: a pivot between cell adhesion and Wnt signalling. Curr Biol 15(2):R64–67
Kemler R (1993) From cadherins to catenins: cytoplasmic protein interactions and regulation of cell adhesion. Trends Genet 9(9):317–321
Lilien J, Balsamo J (2005) The regulation of cadherin-mediated adhesion by tyrosine phosphorylation/dephosphorylation of beta-catenin. Curr Opin Cell Biol 17(5):459–465
Giles RH et al (2003) Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 1653(1):1–24
Logan CY, Nusse R (2004) The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 20:781–810
Nusse R (2005) Cell biology: relays at the membrane. Nature 438(7069):747–749
Polakis P (2000) Wnt signaling and cancer. Genes Dev 14(15):1837–1851
Huang H, He X (2008) Wnt/beta-catenin signaling: new (and old) players and new insights. Curr Opin Cell Biol 20(2):119–125
Liu C et al (2002) Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 108(6):837–847
Aberle H et al (1997) Beta-catenin is a target for the ubiquitin-proteasome pathway. Embo J 16(13):3797–3804
Winston JT et al (1999) The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and beta-catenin and stimulates IkappaBalpha ubiquitination in vitro. Genes Dev 13(3):270–283
Townsley FM et al (2004) Pygopus and Legless target Armadillo/beta-catenin to the nucleus to enable its transcriptional co-activator function. Nat Cell Biol 6(7):626–633
Clevers H, van de Wetering M (1997) TCF/LEF factor earn their wings. Trends Genet 13(12):485–489
Polakis P (1999) The oncogenic activation of beta-catenin. Curr Opin Genet Dev 9(1):515–21
Behrens J, Lustig B (2004) The Wnt connection to tumorigenesis. Int J Dev Biol 48(5–6):477–487
Johnson ML et al (2004) LRP5 and Wnt signaling: a union made for bone. J Bone Miner Res 19(11):1749–1757
Li L et al (1999) Axin and Frat1 interact with dvl and GSK, bridging Dvl to GSK in Wnt-mediated regulation of LEF-1. Embo J 18(15):4233–4240
Kishida S et al (1999) DIX domains of Dvl and axin are necessary for protein interactions and their ability to regulate beta-catenin stability. Mol Cell Biol 19(6):4414–4422
Peifer M, Polakis P (2000) Wnt signaling in oncogenesis and embryogenesis–a look outside the nucleus. Science 287(5458):1606–1609
Aberle H et al (1994) Assembly of the cadherin–catenin complex in vitro with recombinant proteins. J Cell Sci 107(Pt 12):3655–3663
Hulsken J et al (1994) E-cadherin and APC compete for the interaction with beta-catenin and the cytoskeleton. J Cell Biol 127(6 Pt 2):2061–2069
Yost C et al (1996) The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev 10(12):1443–1454
Munemitsu S et al (1996) Deletion of an amino-terminal sequence beta-catenin in vivo and promotes hyperphosphorylation of the adenomatous polyposis coli tumor suppressor protein. Mol Cell Biol 16(8):4088–4094
Rubinfeld B et al (1995) The APC protein and E-cadherin form similar but independent complexes with alpha-catenin, beta-catenin, and plakoglobin. J Biol Chem 270(10):5549–5555
Behrens J et al (1996) Functional interaction of beta-catenin with the transcription factor LEF-1. Nature 382(6592):638–642
Aberle H et al (1996) Single amino acid substitutions in proteins of the armadillo gene family abolish their binding to alpha-catenin. J Biol Chem 271(3):1520–1526
Huber O et al (1996) Nuclear localization of beta-catenin by interaction with transcription factor LEF-1. Mech Dev 59(1):3–10
Molenaar M et al (1996) XTcf-3 transcription factor mediates betacatenin-induced axis formation in Xenopus embryos. Cell 86(3):391–399
van de Wetering M et al (1997) Armadillo coactivates transcription driven by the product of the Drosophila segment polarity gene dTCF. Cell 88(6):789–799
Kraus C et al (1994) Localization of the human beta-catenin gene (CTNNB1) to 3p21: a region implicated in tumor development. Genomics 23(1):272–274
van Hengel J et al (1995) Assignment of the human beta-catenin gene (CTNNB1) to 3p22–>p21.3 by fluorescence in situ hybridization. Cytogenet Cell Genet 70(1–2):68–70
Nollet F et al (1996) Genomic organization of the human beta-catenin gene (CTNNB1). Genomics 32(3):413–424
Zeng L et al (1997) The mouse fused locus encodes Axin, an inhibitor of the Wnt signaling pathway that regulates embryonic axis formation. Cell 90(1):181–192
Salahshor S, Woodgett JR (2005) The links between axin and carcinogenesis. J Clin Pathol 58(3):225–236
Fearnhead NS et al (2001) The ABC of APC. Hum Mol Genet 10(7):721–733
Hsu W et al (1999) Identification of a domain of Axin that binds to the serine/threonine protein phosphatase 2A and a self-binding domain. J Biol Chem 274(6):3439–3445
Zhang Y et al (2002) Casein kinase I and casein kinase II differentially regulate axin function in Wnt and JNK pathways. J Biol Chem 277(20):17706–17712
Satoh S, et al (2000) AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 24(3):245–250
Dong X et al (2001) Genomic structure, chromosome mapping and expression analysis of the human AXIN2 gene. Cytogenet Cell Genet 93(1–2):26–28
Jho EH et al (2002) Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol Cell Biol 22(4):1172–1183
Lustig B et al (2002) Negative feedback loop of Wnt signaling through upregulation of conductin/axin2 in colorectal and liver tumors. Mol Cell Biol 22(4):1184–1193
Yan D et al (2001) Elevated expression of axin2 and hnkd mRNA provides evidence that Wnt/beta-catenin signaling is activated in human colon tumors. Proc Natl Acad Sci USA 98(26):14973–14978
Bienz M (2002) The subcellular destinations of APC proteins. Nat Rev Mol Cell Biol 3(5):328–338
Kinzler KW et al (1991) Identification of FAP locus genes from chromosome 5q21. Science 253(5020):661–665
Groden J et al (1991) Identification and characterization of the familial adenomatous polyposis coli gene. Cell 66(3):589–600
Rubinfeld B et al (1996) Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science 272(5264):1023–1026
Yamamoto H et al (1999) Phosphorylation of axin, a Wnt signal negative regulator, by glycogen synthase kinase-3beta regulates its stability. J Biol Chem 274(16):10681–10684
Rivera MN et al (2007) An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science 315(5812):642–645
Major MB et al (2007) Wilms tumor suppressor WTX negatively regulates WNT/beta-catenin signaling. Science 316(5827):1043–1046
Perotti D et al (2008) Functional inactivation of the WTX gene is not a frequent event in Wilms’ tumors. Oncogene 27(33):4625–4632
Ruteshouser EC et al (2008) Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors. Genes Chromosomes Cancer 47(6):461–470
Jenkins ZA et al (2009) Germline mutations in WTX cause a sclerosing skeletal dysplasia but do not predispose to tumorigenesis. Nat Genet 41(1):95–100
Grohmann A et al (2007) AMER1 regulates the distribution of the tumor suppressor APC between microtubules and the plasma membrane. J Cell Sci 120(Pt 21):3738–3747
Cavallo RA et al (1998) Drosophila Tcf and Groucho interact to repress Wingless signalling activity. Nature 395(6702):604–608
Roose J et al (1998) The Xenopus Wnt effector XTcf-3 interacts with Groucho-related transcriptional repressors. Nature 395(6702):608–612
Chen G et al (1999) A functional interaction between the histone deacetylase Rpd3 and the corepressor Groucho in Drosophila development. Genes Dev 13(17):2218–2230
Hecht A et al (2000) The p300/CBP acetyltransferases function as transcriptional coactivators of beta-catenin in vertebrates. Embo J 19(8):1839–1850
Levy L et al (2004) Acetylation of beta-catenin by p300 regulates beta-catenin-Tcf4 interaction. Mol Cell Biol 24(8):3404–3414
Wolf D et al (2002) Acetylation of beta-catenin by CREB-binding protein (CBP). J Biol Chem 277(28):25562–25567
Lammi L et al (2004) Mutations in AXIN2 cause familial tooth agenesis and predispose to colorectal cancer. Am J Hum Genet 74(5):1043–1050
Mostowska A et al (2006) Axis inhibition protein 2 (AXIN2) polymorphisms may be a risk factor for selective tooth agenesis. J Hum Genet 51(3):262–266
He TC et al (1998) A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 95(5):2509–2514
Shtutman M et al (1999) The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci USA 96(10):5522–5527
Tetsu O, McCormick F (1999) Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398(6726):422–426
Zhang X et al (2001) Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. Cancer Res 61(16):6050–6054
Brabletz T et al (1999) Beta-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am J Pathol 155(4):1033–1038
Conacci-Sorrell ME et al (2002) Nr-CAM is a target gene of the betacatenin/LEF-1 pathway in melanoma and colon cancer and its expression enhances motility and confers tumorigenesis. Genes Dev 16(16):2058–2072
Crawford HC et al (1999) The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. Oncogene 18(18):2883–2891
Moon RT et al (2004) WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 5(9):691–701
Chiang JM et al (2002) Nuclear beta-catenin expression is closely related to ulcerative growth of colorectal carcinoma. Br J Cancer 86(7):1124–1129
Clements WM et al (2002) Beta-catenin mutation is a frequent cause of Wnt pathway activation in gastric cancer. Cancer Res 62(12):3503–3506
Laurent-Puig P et al (2001) Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 120(7):1763–1773
Kartheuser A et al (1999) Familial adenomatous polyposis associated with multiple adrenal adenomas in a patient with a rare 3′ APC mutation. J Med Genet 36(1):65–67
Ono C et al (1991) A case of familial adenomatous polyposis complicated by thyroid carcinoma, carcinoma of the ampulla of vater and adrenocortical adenoma. Jpn J Surg 21(2):234–240
Seki M et al (1992) Loss of normal allele of the APC gene in an adrenocortical carcinoma from a patient with familial adenomatous polyposis. Hum Genet 89(3):298–300
Wakatsuki S et al (1998) Adrenocortical tumor in a patient with familial adenomatous polyposis: a case associated with a complete inactivating mutation of the APC gene and unusual histological features. Hum Pathol 29(3):302–306
Kim AC et al (2008) Targeted disruption of beta-catenin in Sf1-expressing cells impairs development and maintenance of the adrenal cortex. Development 135(15):2593–2602
Gummow BM et al (2003) Convergence of Wnt signaling and steroidogenic factor-1 (SF-1) on transcription of the rat inhibin alpha gene. J Biol Chem 278(29):26572–26579
Kim AC et al (2009) In search of adrenocortical stem and progenitor cells. Endocr Rev 30(3):241–263
Val P, Swain A (2010) Gene dosage effects and transcriptional regulation of early mammalian adrenal cortex development. Mol Cell Endocrinol 323(1):105–114
Beuschlein F et al (1994) Clonal composition of human adrenocortical neoplasms. Cancer Res 54(18):4927–4932
Gicquel C et al (1994) Clonal analysis of human adrenocortical carcinomas and secreting adenomas. Clin Endocrinol (Oxf) 40(4):465–477
Libe R et al (2007) Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer 14(1):13–28
Reincke M et al (1994) p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. J Clin Endocrinol Metab 78(3):790–794
Sidhu S et al (2002) Comparative genomic hybridization analysis of adrenocortical tumors. J Clin Endocrinol Metab 87(7):3467–3474
Kirschner LS et al (2000) Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nat Genet 26(1):89–92
Boulle N et al (1998) Increased levels of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 are associated with malignancy in sporadic adrenocortical tumors. J Clin Endocrinol Metab 83(5):1713–1720
Libe R, Bertherat J (2005) Molecular genetics of adrenocortical tumours, from familial to sporadic diseases. Eur J Endocrinol 153(4):477–487
Gaujoux S et al (2008) Wnt/beta-catenin and 3′,5′-cyclic adenosine 5′-monophosphate/protein kinase A signaling pathways alterations and somatic beta-catenin gene mutations in the progression of adrenocortical tumors. J Clin Endocrinol Metab 93(10):4135–4140
Tadjine M et al (2008) Frequent mutations of beta-catenin gene in sporadic secreting adrenocortical adenomas. Clin Endocrinol (Oxf) 68(2):264–270
Tadjine M et al (2008) Detection of somatic beta-catenin mutations in primary pigmented nodular adrenocortical disease (PPNAD). Clin Endocrinol (Oxf) 69(3):367–373
Tissier F et al (2005) Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res 65(17):7622–7627
Bernichtein S et al (2008) Adrenal gland tumorigenesis after gonadectomy in mice is a complex genetic trait driven by epistatic loci. Endocrinology 149(2):651–661
Bielinska M et al (2005) Gonadotropin-induced adrenocortical neoplasia in NU/J nude mice. Endocrinology 146(9):3975–3984
Groussin L et al (2002) Mutations of the PRKAR1A gene in Cushing’s syndrome due to sporadic primary pigmented nodular adrenocortical disease. J Clin Endocrinol Metab 87(9):4324–4329
Bertherat J et al (2003) Molecular and functional analysis of PRKAR1A and its locus (17q22-24) in sporadic adrenocortical tumors:17q losses, somatic mutations, and protein kinase A expression and activity. Cancer Res 63(17):5308–5319
Bossis I, Stratakis CA (2004) Minireview: PRKAR1A: normal and abnormal functions. Endocrinology 145(12):5452–5458
Horvath A et al (2008) Large deletions of the PRKAR1A gene in Carney complex. Clin Cancer Res 14(2):388–395
Horvath A et al (2006) Serial analysis of gene expression in adrenocortical hyperplasia caused by a germline PRKAR1A mutation. J Clin Endocrinol Metab 91(2):584–596
Iliopoulos D et al (2009) MicroRNA signature of primary pigmented nodular adrenocortical disease: clinical correlations and regulation of Wnt signaling. Cancer Res 69(8):3278–3282
Li G, Iyengar R (2002) Calpain as an effector of the Gq signaling pathway for inhibition of Wnt/beta-catenin-regulated cell proliferation. Proc Natl Acad Sci USA 99(20):13254–13259
Liu J et al (2001) Siah-1 mediates a novel beta-catenin degradation pathway linking p53 to the adenomatous polyposis coli protein. Mol Cell 7(5):927–936
Matsuzawa SI, Reed JC (2001) Siah-1, SIP, and Ebi collaborate in a novel pathway for beta-catenin degradation linked to p53 responses. Mol Cell 7(5):915–926
Hino S et al (2005) Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase stabilizes beta-catenin through inhibition of its ubiquitination. Mol Cell Biol 25(20):9063–9072
Taurin S et al (2006) Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase. J Biol Chem 281(15):9971–9976
Hagen T, Vidal-Puig A (2002) Characterisation of the phosphorylation of beta-catenin at the GSK3 priming site Ser45. Biochem Biophys Res Commun 294(2):324–328
Kikuchi A (2003) Tumor formation by genetic mutations in the components of the Wnt signaling pathway. Cancer Sci 94(3):225–229
Wu R et al (2001) Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas. Cancer Res 61(22):8247–8255
Bourdeau I et al (2004) Gene array analysis of macronodular adrenal hyperplasia confirms clinical heterogeneity and identifies several candidate genes as molecular mediators. Oncogene 23(8):1575–1585
Giordano TJ et al (2003) Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am J Pathol 162(2):521–531
Doghman M et al (2008) The T cell factor/beta-catenin antagonist PKF115-584 inhibits proliferation of adrenocortical carcinoma cells. J Clin Endocrinol Metab 93(8):3222–3225
Bernard MH et al (2003) A case report in favor of a multistep adrenocortical tumorigenesis. J Clin Endocrinol Metab 88(3):998–1001
Gicquel C et al (2001) Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res 61(18):6762–6767
Morin PJ et al (1997) Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275(5307):1787–1790
Smith TG et al (2000) Adrenal masses are associated with familial adenomatous polyposis. Dis Colon Rectum 43(12):1739–1742
Marchesa P et al (1997) Adrenal masses in patients with familial adenomatous polyposis. Dis Colon Rectum 40(9):1023–1028
Traill Z et al (1995) Adrenal carcinoma in a patient with Gardner’s syndrome: imaging findings. AJR Am J Roentgenol 165(6):1460–1461
Lepourcelet M et al (2004) Small-molecule antagonists of the oncogenic Tcf/betacatenin protein complex. Cancer Cell 5(1):91–102
Sukhdeo K et al (2007) Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc Natl Acad Sci USA 104(18):7516–7521
Doghman M et al (2007) Increased steroidogenic factor-1 dosage triggers adrenocortical cell proliferation and cancer. Mol Endocrinol 21(12):2968–2987
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Gaujoux, S., Tissier, F., Bertherat, J. (2009). WNT/β-Catenin Signaling in Adrenocortical Carcinoma. In: Hammer, G., Else, T. (eds) Adrenocortical Carcinoma. Springer, New York, NY. https://doi.org/10.1007/978-0-387-77236-3_16
Download citation
DOI: https://doi.org/10.1007/978-0-387-77236-3_16
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-77235-6
Online ISBN: 978-0-387-77236-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)